Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
| | |||
Abgenix Inc. |
Genentech Inc. (NYSE:DNA) |
Genentech exercised its option to extend for three years a licensing agreement for antibody- eneration technology |
Genentech purchased Abgenix stock, and would pay milestone and royalty fees as products advance; the deal covering Xeno- Mouse technology originally was signed in 1999 (3/14) |
ActiveSight* |
Serenex Inc.* |
Deal for the co-crystallization of Serenex molecules with proteins expressed by ActiveSight |
Additional details of the deal were not disclosed (2/23) |
Aerogen Inc. |
Biota Holdings Ltd. (Australia; ASX:BTA) |
Deal to develop Biota's CS- 958, a long-acting neuraminidase inhibitor, with Aerogen's Aeroneb nebulizer |
Work on the influenza product is being funded under a $5.6M grant to Biota from the National Institutes of Health; terms were not disclosed (3/9) |
Agencourt |
Dyadic International Inc. (OTC BB:DYAD) |
Agencourt will sequence the genome of Dyadic's fungus, Chrysosporium lucknowense, also known as C1 |
The information will be used for potential new protein and enzyme products; terms of the deal were not disclosed (2/17) |
Alnylam |
Benitec Ltd. (Australia; ASX:BLT) |
Benitec and its licensees got an option to nonexclusively license Alnylam-controlled IP in the field of expressed RNA interference |
Alnylam would receive license fees and be entitled to milestone royalty payments on covered products; it also got reciprocal options on Benitec IP for expressed RNAi and synthetic siRNAs (4/12) |
Ambion Inc.* |
Cepheid Inc. (CEPH) |
Cepheid got nonexclusive rights to incorporate Armored RNA technology in its in vitro molecular diagnostic products |
The Ambion Diagnostics division will manufacture custom reagents for Cepheid; terms of the deal were not disclosed (4/11) |
Amrad Corp. |
Serologicals Corp. (SERO) |
Serologicals subsidiary Chemicon International got additional rights to develop embryonic stem cell products into more kits and products |
The expanded deal also included the Walter Eliza Hall Institute of Medical Research; the initial 1999 license covering leukemia inhibitory factor now includes non-therapeutic uses; terms were not disclosed (4/5) |
AnalytiCon |
Bionaut Pharmaceuticals Inc.* |
Collaboration to identify anti- cancer compounds that inhibit the ability of tumor cells to survive stress conditions |
Bionaut will provide and validate compounds that have shown activity; Analyti-Con will optimize them for further preclinical development by Bionaut; terms of the deal were not disclosed (4/14) |
Angiotech |
CABG Medical Inc. (CABG) |
CABG got a license to paclitaxel technology for treating restenosis and proliferative disease |
Angiotech gets a warrant to purchase 1.26M CABG shares, exercisable at $0.01, and potential milestone and royalty payments; also, Angiotech will purchase up to $10M in CABG stock at a 15% premium (3/23) |
Ardais Corp.* |
Cytomyx Holdings plc* (UK) |
Cytomyx is acquiring Ardais' biorepository of more than 130,000 clinically annotated biospecimens |
Cytomyx also will acquire the lab facilities and equipment, and will hire Ardais' biological operations personnel; terms were not disclosed (3/30) |
Array |
Genentech Inc. (NYSE:DNA) |
They expanded collaboration to develop small-molecule drugs against an additional protein target in oncology |
Array gets additional research funding, as well as potential milestone and royalty payments; the January 2004 deal covered two Array oncology programs; Genentech has rights to resulting products (4/7) |
Avidex Ltd.* |
Active Biotech AB (Sweden; SSE:ACTI) |
Active will use Avidex's monoclonal T-cell receptor technology to help develop the cancer product Anyara |
Avidex's mTCR product will be used for characterization of the drug during clinical development; terms were not disclosed (3/7) |
BCY Life- |
Align Pharmaceuticals Inc.* |
Align will further develop and market BCY's DCF 987, a Phase II product for respiratory conditions |
BCY is entitled to up-front, milestone and royalty payments; the product is the first in Align's portfolio (2/25) |
Benitec Ltd. |
GenOway SA* (France) |
GenOway got rights to develop transgenic animals using DNA-directed RNA interference |
Benitec gets an up-front license fee and ongoing royalties under the worldwide, non-exclusive deal (3/22) |
BioFocus plc |
Senexis Ltd.* (UK) |
Deal to accelerate lead discovery of Senexis drugs for Alzheimer's disease |
Terms of the deal were not disclosed (3/7) |
Caliper Life |
Amphora Discovery Corp.* |
Amphora agreed to purchase a certain amount of LabChip products over two years |
Terms of the deal were not disclosed (4/14) |
Caprion |
ICOS Corp. (ICOS) |
Collaboration for the joint development of therapeutic antibodies for treating cancer |
Caprion gets an up-front payment and license fees; the deal includes reciprocal milestone and royalty payments; also, ICOS has an option to co-develop and co-promote certain products (3/31) |
Celgene Corp. |
EntreMed Inc. (ENMD) |
EntreMed licensed rights to Celgene's small-molecule tubulin inhibitor compounds for the treatment of cancer |
Celgene gets an up-front licensing fee and potential milestone payments under the worldwide, exclusive deal (3/24) |
CeNeS |
Tripos Inc. (TRPS) |
They entered a new deal to continue a collaboration to advance discovery of COMT inhibitors |
They already have identified series of compounds active against the target catechol-O-methyltransferase; now they will optimize those compounds (4/14) |
ChemDiv |
Dendreon Corp. (DNDN) |
They expanded and extended deal under which ChemDiv supplies chemistry services to Dendreon |
The services support Dendreon's discovery programs for targeted cancer therapies; terms of the deal were not disclosed (4/1) |
Chicago Labs |
Spectrum Pharmaceuticals Inc. (SPPI) |
Spectrum acquired an exclusive license to endothelin B agonists for the treatment of cancer |
Chicago Labs, which licensed the technology from the University of Illinois, gets $100,000 up front, along with potential milestone and royalty payments (2/18) |
CombiMatrix |
Benitec Ltd. (Australia; ASX:BLT) |
Benitec got a nonexclusive license to use pools of siRNAs against viral diseases, and a coexclusive sublicense to two sequences targeting HIV genes |
In return, CombiMatrix got a nonexclusive license to patents for the development of RNAi therapeutics against diseases resulting from biological, chemical, radioactive and other weapons; the companies also will collaborate in other areas (2/22) |
Corixa Corp. |
Panbio Ltd. (Australia; ASX:PBO) |
Panbio acquired technology to help in the development of assays for the diagnosis of two tick-borne diseases |
Corixa gets an up-front payment, annual maintenance payments and royalties on any resulting product sales (4/12) |
Corixa Corp. |
Lorantis Ltd.* (UK) |
Deal to continue development of a hepatitis B vaccine containing Corixa's RC-529 adjuvant and Lorantis' CV-1831, a hepatitis B core antigen |
The antigen previously was owned by Apovia Inc.; Lorantis acquired Apovia's interest in the technology and will assume many of Apovia's responsibilities under the deal with Corixa; Lorantis and Corixa will share costs and revenues (3/3) |
Cortendo |
DiObex Inc.* |
DiObex licensed worldwide rights to inhibitors of cortisol synthesis |
The technology has applications in metabolic diseases; terms of the deal were not disclosed (4/11) |
Cresset |
Pharmagene plc (UK; LSE: PGN) |
Cresset will attempt to find novel leads against a Pharmagene discovery target |
Terms of the deal were not disclosed (3/2) |
Crucell NV |
Vascular Biogenics Ltd.* (Israel) |
Vascular Biogenics got rights to use the PER.C6 cell line in gene therapeutics based on adenoviral vectors |
Crucell gets a research license payment and annual license fees in the nonexclusive deal (3/30) |
Crucell NV |
SingVax Pte. Ltd. (Singapore) |
SingVax got rights to PER.C6 technology for use in vaccines against Japanese encephalitis |
Crucell gets up-front, annual and potential milestone payments, as well as royalties on any sales and a preferred position to negotiate marketing rights outside the Asia- Pacific region (3/22) |
Curis Inc. |
Genentech Inc. (NYSE:DNA) |
Collaboration to develop small- molecule modulators of an undisclosed pathway involved in cell proliferation; the pathway is a regulator of tissue formation and repair |
Curis gets an up-front license fee of $3M and up to $6M more over two years in research support; Curis also could get milestone and royalty payments; the deal, excluding royalties, could be worth $140M to Curis if two products are developed in two indications each; Curis also retains certain rights (4/4) |
Cytos |
Medarex Inc. (MEDX) |
They expanded the scope of a November 2002 deal focused on drug targets for immunological diseases to include targets in other areas of interest |
Cytos gets an up-front payment, and can earn license fees, milestones and royalties; Medarex gets exclusive rights for monoclonal antibodies against the targets, and the first right of negotiation for use of the targets in small- olecule drug discovery and as protein therapeutics (4/1) |
Demegen Inc.* |
Pacgen Bio- pharmaceuticals Corp.* (Canada) |
Pacgen got a license to certain peptides for treating oral diseases |
Pacgen's initial focus will be on a treatment for oral candidiasis; terms of the deal were not disclosed (3/22) |
Diabetogen |
TolerRx Inc.* |
TolerRx acquired rights to the therapeutic use of anti- CD3 antibodies in autoimmune diseases |
TolerRx also got rights to a panel of fully human anti-CD3 antibodies under a licensing agreement between Diabetogen and Abgenix Inc.; terms of the deal were not disclosed (4/4) |
Directif GmbH |
Epidauros Biotechnologie AG* (Germany) |
They formed a joint venture to develop applications for Directif's LabChip technology in personalized medicine |
They are pooling know-how to develop applications for drug development; terms were not disclosed (3/23) |
Discovery |
Chroma Therapeutics Ltd.* (UK) |
DPI will use its compound collection and other technologies to identify compounds for Chroma targets |
Terms of the deal were not disclosed (3/29) |
Domantis Ltd.* |
Tanox Inc. (TNOX) |
Domantis will use its Domain Antibodies technology to discover therapeutic product leads for Tanox |
Domantis gets an up-front fee, research funding and annual fees, as well as potential milestone and royalty payments; the focus is autoimmune diseases (3/22) |
Durect Corp. |
Endo Pharmaceuticals Inc. (ENDP) |
Endo got exclusive rights to Durect's sufentanil-containing transdermal patch in the U.S. and Canada |
Durect gets $10M up front and up to $35M in regulatory and commercial milestones, as well as royalties on any sales of the pain product; Endo assumed development responsibilities (3/14) |
EndoChem |
QuatRx Pharmaceuticals Co.* |
QuatRx acquired rights to QRX-431, an orally active compound for the treatment of lipid disorders and obesity |
Terms of the exclusive worldwide deal were not disclosed (3/15) |
Enlyton Ltd.* |
Neoprobe Corp. (OTC BB:NEOP) |
Neoprobe licensed two patents that are related to its RIGS technology |
The deal provides Neoprobe with an extension of methodology patent protection for the technology; terms were not disclosed (4/5) |
Galmed |
BioLineRx Ltd.* (Israel) |
BioLineRx licensed worldwide rights to BL- 060, a small molecule for treating fatty liver disease |
Terms of the exclusive deal on the preclinical product were not disclosed (3/14) |
Genaissance |
ParAllele BioScience Inc.* |
License and co-marketing agreement to provide genetic screening technology and services |
ParAllele is licensing more than 400 SNPs from Genaissance, and combining them with certain public-domain SNPs in an assay panel; Genaissance will be the first company to offer the panel for research uses (4/6) |
Geron Corp. |
Exeter Life Sciences Inc.* |
They formed a new company named stART Licensing Inc. for licensing animal cloning technologies |
The portfolio includes nuclear transfer cloning technology developed at the Roslin Institute; Exeter will provide additional capital for the effort, and own 50.1% of the company; Geron also can get up-front and milestone payments (4/6) |
HTS Biosystems |
Biacore International AB (Sweden; SSE:BCOR) |
Biacore acquired the FLEXChip System and related assets from HTS |
Biacore is paying $4M for the technology used in protein-interaction analysis (3/10) |
Icoria Inc. |
Admet Technologies Inc.* |
Icoria will characterize Admet's human adult hepatocytes to improve their value as a predictive toxicology screening tool |
Admet will use the information to identify cells that could be used in toxicology assays; Icoria retains rights to develop any resulting novel diagnostic biomarkers (4/19) |
Invitrogen |
Plexxikon Inc.* |
Invitrogen will provide kinase screening services on Plexxikon kinase inhibitor libraries |
Plexxikon intends to develop drugs for oncology, inflammation and other diseases; terms of the service agreement were not disclosed (4/6) |
IriSys Inc.* |
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
Avanir acquired additional rights to its late- stage CNS product Neurodex |
Avanir licensed the product from IriSys in 2000; it has no further obligation to IriSys after paying $1.925M in cash and 2M shares of stock; Avanir still has royalty and other obligations to the discoverer, The Center for Neurologic Study (3/9) |
Isis |
OncoGenex Technologies Inc.* |
They broadened collaboration to allow for development of two additional second- eneration antisense cancer drugs |
Isis gets an up-front fee along with potential milestone and royalty payments; two drugs already are being developed under the deal that started in 2001 (3/16) |
Large Scale |
Icon Genetics AG* (Germany) |
Deal to combine technologies to develop an undisclosed product |
They will pool their plant-based platforms in an attempt to develop the difficult-to- produce drug; terms were not disclosed (3/1) |
MorphoSys |
Jerini AG* (Germany) |
Co-marketing deal between MorphoSys division Antibodies by Design and Jerini subsidiary JPT Peptide Technologies GmbH |
They will co-market monoclonal antibodies generated by Antibodies by Design and the complementary peptide-based services and products from JPT; each will offer the services of the other (4/18) |
Morphotek |
Amgen Inc. (AMGN) |
Morphotek will apply its technology to Amgen cell lines to develop high-titer antibody-producing cell lines |
Morphotek gets research payments and is entitled to milestone payments in the deal, which is focused on producing cell lines for scalable manufacturing (4/18) |
Mutabilis SA* (France) |
Chiron Corp. |
Chiron Vaccines licensed rights to use Mutabilis technology in development of a prophylactic vaccine |
Mutabilis is entitled to license fees, milestone payments and royalties on any sales; the target was not disclosed (4/11) |
Nanogen Inc. |
DeCode Genetics Inc. (Iceland; DCGN) |
Nanogen will provide a new genomics assay for single nucleotide polymorphism discovery and screening |
Terms of the supply and license agreement were not disclosed (4/18) |
NascaCell IP |
Discovery Partners International Inc. (DPII) |
Deal to jointly provide aptamer-based drug discovery services to the life sciences industry |
The effort combines NascaCell's expertise in aptamers with DPI's drug discovery capabilities; terms were not disclosed (3/21) |
Neuren |
Metabolic Pharmaceuticals Ltd. (Australia; ASX:MBP) |
Deal to co-develop Neuren's neuroregenerative peptides for treating degenerative conditions |
They will jointly develop the technology and equally share all intellectual property and commercial outcomes (3/4) |
Pathway |
Nanogen Inc. (NGEN) |
Deal under which Nanogen will develop diagnostics that detect genetic variations associated with responses to depression and psychosis drugs |
Terms of the nonexclusive, worldwide license agreement were not disclosed (3/22) |
Pharmacopeia |
CV Therapeutics Inc. (CVTX) |
Drug discovery deal under which Pharmacopeia will provide discovery technologies |
Pharmacopeia gets research funding in addition to potential milestone and royalty payments (3/23) |
Pintex |
Vernalis plc (UK; VNLS) |
Vernalis acquired rights and other assets related to the oncology target Pin1 |
Pintex gets an initial cash payment, and would get up to 1.5M Vernalis shares should a drug candidate enter human trials, which is not expected before 2008; Pintex would get another payment, bringing the total to $6.5M, upon product approval (3/31) |
Prostagenics |
Innovate Oncology Inc. (OTC BB:IOVO) |
Innovate acquired rights to capridine-beta, a nitroacridine derivative, for treating prostate cancer |
Phase I trials for the drug are being planned; terms of the deal were not disclosed (4/8) |
Protein Design |
Seattle Genetics Inc. (SGEN) |
Seattle Genetics got exclusive rights to PDL's anti-CD33 program for both unconjugated antibody and antibody-drug conjugate applications |
PDL gets an up-front fee and is entitled to milestone and royalty payments; the pre-clinical program has applications in cancer; also, royalties payable by PDL under an existing collaboration were reduced (4/13) |
Protein Polymer |
Genencor International Inc. (GCOR) |
They expanded 2000 deal to include personal care product applications |
Genencor already had rights to industrial applications of PPTI's polymer technology; PPTI gets an up-front and annual payments, as well as royalties on any sales (3/30) |
ProteoCell |
Viropro Inc. (Canada; OTC BB:VPRO) |
Deal to commercialize recombinant biogeneric therapeutics for international markets |
They intend to evaluate and scale up certain biotherapeutic proteins, then transfer candidates to international clients for local commercial manufacturing (3/15) |
QLT Inc. |
VasoGenix Pharmaceuticals Inc.* |
Deal to develop a sustained- release formulation of Vaso-Genix's calcitonin gene- related peptide |
QLT will develop the delivery system for CGRP; VasoGenix has the option to acquire an exclusive worldwide royalty-bearing license to the product (4/11) |
Quadrant Drug |
CoTherix Inc. (CTRX) |
Deal to develop an extended-release formulation of CoTherix's Ventavis |
The product is approved for treating pulmonary arterial hypertension; terms of the deal were not disclosed (4/5) |
ReOx Ltd.* |
Unnamed U.S.- based company |
Deal to co-develop drugs targeting cellular oxygen regulation through the transcription factor hypoxia inducible factor |
ReOx is getting $9M up front and is entitled to research funding, milestone payments and royalties on any resulting sales; the research has applicability in a number of diseases (4/18) |
Revaax |
Rexahn Corp.* |
Rexahn licensed technology similar to antibiotics with activity against central nervous system activity |
The lead compound, RX-10,100, is expected to enter clinical trials within a year; terms of the deal were not disclosed (3/3) |
RheoGene |
TissueGene Inc.* |
Research and license agreement to develop regulated cell therapy treatments for bone restoration and repair |
The effort will combine TissueGene's cell therapy technology and RheoGene's Rheo-Switch Therapeutic System to develop non- surgical treatments for non-union bone fractures, bone wounds and osteoporosis (4/19) |
Scynexis Inc.* |
Adherex Technologies Inc. (AMEX:ADH) |
Scynexis will provide medicinal and analytical chemistry services to Adherex |
The work will focus on Adherex's small- molecule cadherin antagonist development programs; terms were not disclosed (3/23) |
Serologicals |
OncoMethylome Sciences SA* (Belgium) |
OMS licensed fluorescent detection technology for development of diagnostic assays for detecting DNA methylation patterns |
OMS made the deal on the Amplifluor technology with Serologicals subsidiary Chemicon International Inc.; terms of the deal were not disclosed (3/30) |
Sigmoid |
Inncardio Inc. (OTC BB:INDO) |
Deal to develop new formulations of established drugs using Sigmoid's delivery and formulation technology |
Neither the drugs nor the terms of the deal were disclosed (4/18) |
Sunol Molecular Corp.* |
Tanox Inc. (TNOX) |
Tanox is acquiring Sunol's tissue factor antagonist program for treating inflammatory diseases and cancer |
Tanox will issue 800,000 shares of common stock, which were valued at $8.26M, and pay $6 million to Sunol in the deal; Tanox also got nonexclusive rights to certain technologies for protein and antibody expression (3/28) |
Syntonix |
Serono SA (Switzerland; NYSE:SRA) |
Serono licensed exclusive rights to Transceptor and Synfusion technologies for developing interferon-beta:Fc products |
Serono intends to develop an inhaled interferon-beta therapy for multiple sclerosis; Syntonix gets an up-front license fee and is eligible for development milestones and sales royalties (3/31) |
VASTox plc |
Undisclosed company |
VASTox will target drugs to specific organs and cell types through the use of sugars |
VASTox will perform the work under a nine-month fee-for-service deal with the unnamed European company (2/23) |
ViaCell Inc. |
Genzyme Corp. (GENZ) |
Collaboration related to use of islet stem cells for treating diabetes |
The companies will conduct preclinical research in the area; terms of the deal were not disclosed (3/15) |
Xantos |
NascaCell IP GmbH* (Germany) and PSF Biotech AG* (Germany) |
The three companies formed a consortium to identify and develop new drugs for the inhibition of tumor angiogenesis |
The collaboration, using an aptamer-based approach, will integrate the technology platforms of the three companies; the PADDION consortium will receive initial funding from the BioChancePlus program of the German Federal Ministry of Education and Research (4/13) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.